Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose-Reference-Cited by-同舟云学术

Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose

Published:2007-07 Issue:1-2 Volume:258 Page:137-143
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Pahwa Rajesh,Koller William C.,Trosch Richard M.,Sherry James H.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference16 articles.

1. Subcutaneous apomorphine. An evidence-based review of its use in Parkinson's disease;Deleu;Drugs Aging,2004

2. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature;Ahlskog;Mov Disord,2001

3. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management;van Laar;CNS Drugs,2003

4. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa;Melamed;J Neural Transm Suppl,1999

5. Prevention and treatment of motor fluctuations;Stocchi;Parkinsonism Relat Disord,2003

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology;Journal of Neurology;2024-08-29

2. Potentiometric detection of apomorphine in human plasma using a 3D printed sensor;Biosensors and Bioelectronics;2024-03

3. Daytime sleepiness in Parkinson's disease: a multifaceted symptom;Frontiers in Sleep;2023-12-22

4. Management of OFF condition in Parkinson disease;Mental Health Clinician;2023-12-01

5. Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease;Expert Opinion on Drug Safety;2023-07-03